Scroll Top

2024 News Release

Gain Therapeutics Inc.

2024 News Release 2023 News Release 2022 News Release 2021 News Release 2020 News Release 2019 News Release 2025 News Release

December 23, 2024

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

December 11, 2024

Gain Therapeutics To Present At Biotech Showcase 2025

November 14, 2024

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

October 23, 2024

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

October 15, 2024

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 9, 2024

Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference

October 7, 2024

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

October 3, 2024

Gain Therapeutics to Participate at Upcoming Investor Conferences

February 27, 2024

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

February 14, 2024

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

February 6, 2024

UPDATE – Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

February 6, 2024

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

January 31, 2024

Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

January 2, 2024

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024